{"id":"prednylidene","rwe":[],"tags":[{"label":"prednylidene","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"H02AB11","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dacorsol","offLabel":[],"synonyms":["prednylidene","dacorsol","dacortilen","decortilen"],"timeline":[],"approvals":[],"brandName":"Dacorsol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"prednylidene","explanation":"Imagine your body's cells have locks on them, and Dacorsol is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock open or closed, depending on the type of lock and the key's shape. This can affect how the cell behaves and responds to signals, but the exact details of how Dacorsol works are still being studied.","oneSentence":"Dacorsol is thought to work by interacting with a specific cellular target, although its exact mechanism of action is not well understood.","technicalDetail":"As a prednylidene compound, Dacorsol is likely to exert its effects through modulation of steroid hormone receptors or other signaling pathways, although the specific molecular mechanisms involved are not yet well characterized."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2254","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PREDNYLIDENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PREDNYLIDENE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:25:12.996741","biosimilars":[],"competitors":[{"drugName":"betamethasone","drugSlug":"betamethasone","fdaApproval":"1961-04-17","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dexamethasone","drugSlug":"dexamethasone","fdaApproval":"1958-10-30","patentExpiry":"Oct 7, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"methylprednisolone","drugSlug":"methylprednisolone","fdaApproval":"1957-10-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"paramethasone acetate","drugSlug":"paramethasone-acetate","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"prednisolone","drugSlug":"prednisolone","fdaApproval":"1955-06-21","genericCount":42,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"prednisone","drugSlug":"prednisone","fdaApproval":"1955-02-21","patentExpiry":"Jan 7, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"triamcinolone","drugSlug":"triamcinolone","fdaApproval":"1957-12-03","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydrocortisone","drugSlug":"hydrocortisone","fdaApproval":"1952-08-05","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rimexolone","drugSlug":"rimexolone","fdaApproval":"1994-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"deflazacort","drugSlug":"deflazacort","fdaApproval":"2017-02-09","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"meprednisone","drugSlug":"meprednisone","fdaApproval":"1978-01-26","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"prednylidene","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"betamethasone","brandName":"betamethasone","genericName":"betamethasone","approvalYear":"1961","relationship":"same-class"},{"drugId":"dexamethasone","brandName":"dexamethasone","genericName":"dexamethasone","approvalYear":"1958","relationship":"same-class"},{"drugId":"methylprednisolone","brandName":"methylprednisolone","genericName":"methylprednisolone","approvalYear":"1957","relationship":"same-class"},{"drugId":"paramethasone-acetate","brandName":"paramethasone acetate","genericName":"paramethasone acetate","approvalYear":"","relationship":"same-class"},{"drugId":"prednisolone","brandName":"prednisolone","genericName":"prednisolone","approvalYear":"1955","relationship":"same-class"},{"drugId":"prednisone","brandName":"prednisone","genericName":"prednisone","approvalYear":"1955","relationship":"same-class"},{"drugId":"triamcinolone","brandName":"triamcinolone","genericName":"triamcinolone","approvalYear":"1957","relationship":"same-class"},{"drugId":"hydrocortisone","brandName":"hydrocortisone","genericName":"hydrocortisone","approvalYear":"1952","relationship":"same-class"},{"drugId":"rimexolone","brandName":"rimexolone","genericName":"rimexolone","approvalYear":"1994","relationship":"same-class"},{"drugId":"deflazacort","brandName":"deflazacort","genericName":"deflazacort","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":349,"completionDate":"2026-12-31"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT03984448","phase":"PHASE2,PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double-Expressor Lymphoma","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":363,"completionDate":"2028-04-01"},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":["High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified","Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified","Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"],"enrollment":120,"completionDate":"2027-09-01"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":["Acute Adult T-Cell Leukemia/Lymphoma","Adult T-Cell Leukemia/Lymphoma","Chronic Adult T-Cell Leukemia/Lymphoma","HTLV-1 Infection"],"enrollment":30,"completionDate":"2027-06-30"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Recurrent Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":53,"completionDate":"2027-01-26"},{"nctId":"NCT05896839","phase":"PHASE1,PHASE2","title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-24","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Metastatic Basal Cell Carcinoma","Metastatic Carcinoma in the Skin","Metastatic Melanoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Unresectable Basal Cell Carcinoma","Unresectable Melanoma","Unresectable Merkel Cell Carcinoma","Unresectable Skin Squamous Cell Carcinoma"],"enrollment":16,"completionDate":"2027-01-31"},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":["Ann Arbor Stage IIB Hodgkin Lymphoma","Ann Arbor Stage IIIB Hodgkin Lymphoma","Ann Arbor Stage IVA Hodgkin Lymphoma","Ann Arbor Stage IVB Hodgkin Lymphoma","Childhood Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":600,"completionDate":"2026-10-03"},{"nctId":"NCT06124157","phase":"PHASE2","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT06235567","phase":"PHASE1,PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":["Keratoconus"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1","Lymphoblastic Lymphoma"],"enrollment":33,"completionDate":"2028-07-31"},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":["Kidney Transplant"],"enrollment":800,"completionDate":"2029-07"},{"nctId":"NCT04799275","phase":"PHASE2,PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":["Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Grade 3b Follicular Lymphoma","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Intravascular Large B-Cell Lymphoma","Lymphoplasmacytic Lymphoma","Nodular Lymphocyte Predominant B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":422,"completionDate":"2027-03-01"},{"nctId":"NCT03360721","phase":"PHASE2","title":"Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-03-06","conditions":["Castration-Resistant Prostate Carcinoma","Prostate Adenocarcinoma Without Neuroendocrine Differentiation","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":7,"completionDate":"2026-03-12"},{"nctId":"NCT06173362","phase":"PHASE2","title":"Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-11-09","conditions":["Advanced Prostate Adenocarcinoma","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":75,"completionDate":"2027-05"},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":30,"completionDate":"2031-05-01"},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","T Acute Lymphoblastic Leukemia"],"enrollment":30,"completionDate":"2028-07-30"},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma in the Soft Tissue","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":223,"completionDate":"2026-04-01"},{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":["Clinical Stage 0 Cutaneous Melanoma AJCC v8","Clinical Stage I Cutaneous Melanoma AJCC v8","Clinical Stage IA Cutaneous Melanoma AJCC v8","Clinical Stage IB Cutaneous Melanoma AJCC v8","Clinical Stage II Cutaneous Melanoma AJCC v8","Clinical Stage IIA Cutaneous Melanoma AJCC v8","Clinical Stage IIB Cutaneous Melanoma AJCC v8","Clinical Stage IIC Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Colitis","Lung Non-Small Cell Carcinoma","Malignant Genitourinary System Neoplasm","Malignant Solid Neoplasm","Pathologic Stage 0 Cutaneous Melanoma AJCC v8","Pathologic Stage I Cutaneous Melanoma AJCC v8","Pathologic Stage IA Cutaneous Melanoma AJCC v8","Pathologic Stage IB Cutaneous Melanoma AJCC v8","Pathologic Stage II Cutaneous Melanoma AJCC v8","Pathologic Stage IIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIC Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Stage 0 Lung Cancer AJCC v8","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8"],"enrollment":800,"completionDate":"2026-10-31"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":["Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","PSA Progression","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":196,"completionDate":"2028-03-31"},{"nctId":"NCT05157971","phase":"PHASE1","title":"Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-03-17","conditions":["B Acute Lymphoblastic Leukemia","Ph-Like Acute Lymphoblastic Leukemia"],"enrollment":24,"completionDate":"2026-05-12"},{"nctId":"NCT07451665","phase":"PHASE4","title":"Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2026-04-01","conditions":["Takayasu Arteritis (TAK)"],"enrollment":180,"completionDate":"2029-03-31"},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"enrollment":40,"completionDate":"2026-12-31"},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":["Multiple Myeloma"],"enrollment":306,"completionDate":"2026-02-22"},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":["Autoimmune Disease","Neurologic Autoimmune Disease","Autologous Transplant Autoimmune","Multiple Sclerosis Transplant","MS Stem Cell Transplant","Multiple Sclerosis Stem Cell Transplant","Stiff Person Syndrome","HCT for Neurologic Autoimmune Disorders","CIDP Transplant","Myasthenia Gravis Transplant","Autoimmune Nervous System Disorder","Central Nervous System Vasculitis","Cerebellar Degeneration","Chronic Inflammatory Demyelinating Polyneuropathy","Lambert Eaton Myasthenic Syndrome","Myasthenia Gravis","Neuromyelitis Optica","Opsoclonus Myoclonus Syndrome","Rasmussen Subacute Encephalitis"],"enrollment":53,"completionDate":"2030-01-31"},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Steroid-Refractory Pneumonitis"],"enrollment":1,"completionDate":"2023-12-21"},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":["Recurrent Prostate Carcinoma","Stage III Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":72,"completionDate":"2029-07-01"},{"nctId":"NCT02522715","phase":"PHASE1,PHASE2","title":"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-08-13","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7"],"enrollment":37,"completionDate":"2027-01-01"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":["Prostate Adenocarcinoma","Recurrent Prostate Carcinoma"],"enrollment":310,"completionDate":"2027-02-01"},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":["Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma"],"enrollment":31,"completionDate":"2027-08-03"},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":["Prostate Carcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8"],"enrollment":200,"completionDate":"2026-06-07"},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":["Mantle Cell Lymphoma"],"enrollment":55,"completionDate":"2020-06"},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":["Vitreoretinal Surgery","Ocular Inflammation","Post-operative Pain","Post-Operative Inflammation"],"enrollment":30,"completionDate":"2026-05-01"},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Mixed Phenotype Acute Leukemia","Recurrent B Acute Lymphoblastic Leukemia","Recurrent Mixed Phenotype Acute Leukemia"],"enrollment":20,"completionDate":"2026-12-02"},{"nctId":"NCT03749018","phase":"PHASE2","title":"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bond, MD","startDate":"2019-01-02","conditions":["Aggressive Non-Hodgkin Lymphoma","Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma","Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Indolent Non-Hodgkin Lymphoma","Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","Transformed Non-Hodgkin Lymphoma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT04850495","phase":"PHASE1","title":"Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"Yazeed Sawalha","startDate":"2021-11-16","conditions":["Diffuse Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":38,"completionDate":"2026-06-15"},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":["IgG4 Related Disease","IgG4-RD"],"enrollment":8,"completionDate":"2024-01-04"},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Follicular Lymphoma","Ann Arbor Stage II Marginal Zone Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage III Marginal Zone Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Ann Arbor Stage IV Marginal Zone Lymphoma","Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","Indolent Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2028-05-16"},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":70,"completionDate":"2027-08-23"},{"nctId":"NCT06470243","phase":"PHASE3","title":"Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-11-27","conditions":["Castration-Resistant Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":528,"completionDate":"2034-04"},{"nctId":"NCT04267887","phase":"PHASE2","title":"Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-05-11","conditions":["Castration-Sensitive Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":7,"completionDate":"2030-01-01"},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":["B-Cell Non-Hodgkin Lymphoma","Burkitt Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Primary Mediastinal Large B-Cell Lymphoma","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce"],"enrollment":18,"completionDate":"2030-05-31"},{"nctId":"NCT04151082","phase":"PHASE1,PHASE2","title":"High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-16","conditions":["Cranial Nerve Disorder","Head and Neck Carcinoma","Oropharyngeal Carcinoma"],"enrollment":35,"completionDate":"2027-07-31"},{"nctId":"NCT03808610","phase":"PHASE1,PHASE2","title":"Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-03","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT05689021","phase":"PHASE2","title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-05","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":8,"completionDate":"2026-03-31"},{"nctId":"NCT00501826","phase":"PHASE2","title":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-11","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":160,"completionDate":"2026-10-31"},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":["Stage II Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma"],"enrollment":90,"completionDate":"2027-06"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT06600802","phase":"NA","title":"Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Centre Jean Perrin","startDate":"2024-10-08","conditions":["Castration-resistant Metastatic Prostate Cancer","Treated by 177Lutetium-PSMA-617 (Lu-PSMA)"],"enrollment":120,"completionDate":"2034-06-30"},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":["Recurrent Castration-Sensitive Prostate Carcinoma","Recurrent Prostate Cancer","Castration-resistant Prostate Cancer","Biochemically Recurrent Prostate Carcinoma"],"enrollment":532,"completionDate":"2029-05-31"},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Refractory Acute Leukemia of Ambiguous Lineage","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged","Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia","Refractory Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2027-12-31"},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":["Precursor Cell Lymphoblastic Leukemia-Lymphoma"],"enrollment":53,"completionDate":"2028-12-31"},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":["Follicular Helper T-Cell Lymphoma","Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","Follicular Helper T-Cell Lymphoma, Follicular-Type","Follicular Helper T-Cell Lymphoma, Not Otherwise Specified","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":20,"completionDate":"2027-03-31"},{"nctId":"NCT01424982","phase":"PHASE2","title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10-05","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Adult Acute Lymphoblastic Leukemia in Complete Remission","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Untreated Adult Acute Lymphoblastic Leukemia"],"enrollment":88,"completionDate":"2027-10-31"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":["Non-Hodgkin's Lymphoma","Hematopoietic Stem Cell Mobilization"],"enrollment":99,"completionDate":"2026-08"},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"],"enrollment":488,"completionDate":"2026-03-25"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT05600686","phase":"PHASE2","title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2023-05-24","conditions":["Double-Expressor Lymphoma","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements"],"enrollment":24,"completionDate":"2028-02-01"},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":["Adult T-Cell Leukemia/Lymphoma","Anaplastic Large Cell Lymphoma, ALK-Negative","Anaplastic Large Cell Lymphoma, ALK-Positive","Angioimmunoblastic T-Cell Lymphoma","Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma","Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma","Enteropathy-Associated T-Cell Lymphoma","Hepatosplenic T-Cell Lymphoma","Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","Peripheral T-Cell Lymphoma, Not Otherwise Specified"],"enrollment":48,"completionDate":"2026-07-07"},{"nctId":"NCT03933631","phase":"PHASE3","title":"Pilocarpine Use After Kahook Goniotomy","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2019-05-01","conditions":["Glaucoma"],"enrollment":142,"completionDate":"2028-12"},{"nctId":"NCT02877303","phase":"PHASE2","title":"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-01","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2026-11-01"},{"nctId":"NCT03480646","phase":"PHASE1,PHASE2","title":"ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2017-11-15","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"enrollment":175,"completionDate":"2021-02-03"},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":62,"completionDate":"2027-01-16"},{"nctId":"NCT07220187","phase":"PHASE3","title":"Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-02","conditions":["Richter Syndrome","Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":102,"completionDate":"2036-10"},{"nctId":"NCT03821792","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-22","conditions":["Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":60,"completionDate":"2026-10-11"},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":["B-cell Lymphoma","Burkitt Lymphoma"],"enrollment":11,"completionDate":"2027-10-11"},{"nctId":"NCT03816332","phase":"PHASE1","title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-08","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Metastatic Basal Cell Carcinoma","Metastatic Melanoma","Metastatic Merkel Cell Carcinoma","Metastatic Skin Squamous Cell Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8","Unresectable Basal Cell Carcinoma","Unresectable Melanoma","Unresectable Merkel Cell Carcinoma"],"enrollment":12,"completionDate":"2026-09-19"},{"nctId":"NCT00107198","phase":"PHASE2","title":"Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2006-01-02","conditions":["Ann Arbor Stage I Childhood Hodgkin Lymphoma","Ann Arbor Stage II Childhood Hodgkin Lymphoma","Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma"],"enrollment":188,"completionDate":"2030-12-31"},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":["Castration Levels of Testosterone","Metastatic Prostatic Adenocarcinoma","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":1273,"completionDate":"2031-10-01"},{"nctId":"NCT00972478","phase":"PHASE1,PHASE2","title":"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-15","conditions":["Ann Arbor Stage II Non-Hodgkin Lymphoma","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma"],"enrollment":83,"completionDate":"2026-03-06"},{"nctId":"NCT07136805","phase":"PHASE3","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2025-10-01","conditions":["Non-infectious Anterior Uveitis"],"enrollment":152,"completionDate":"2027-04-30"},{"nctId":"NCT03505762","phase":"PHASE2","title":"Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-07-19","conditions":["B-Cell Non-Hodgkin Lymphoma"],"enrollment":80,"completionDate":"2025-11"},{"nctId":"NCT05620901","phase":"EARLY_PHASE1","title":"DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia","status":"COMPLETED","sponsor":"Lejla Vajzovic, MD, FASRS","startDate":"2023-02-01","conditions":["Vitreoretinopathy","Coats' Disease","Exudative Retinopathy","Lattice Degeneration","Retinal Hole","Sickler's Syndrome","Retinal Detachment Rhegmatogenous","Retinal Detachment Exudative","Retinal Detachment Traction"],"enrollment":16,"completionDate":"2025-02-24"},{"nctId":"NCT06172361","phase":"PHASE3","title":"Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":["Polymyalgia Rheumatica"],"enrollment":98,"completionDate":"2026-01-30"},{"nctId":"NCT05032183","phase":"PHASE1,PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":["Recurrent Adult Lymphoblastic Lymphoma","Recurrent B Acute Lymphoblastic Leukemia","Recurrent T Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Lymphoblastic Lymphoma","Refractory T Acute Lymphoblastic Leukemia"],"enrollment":4,"completionDate":"2024-07-31"},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":["AIDS-Related Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":46,"completionDate":"2026-07-16"},{"nctId":"NCT04139304","phase":"EARLY_PHASE1","title":"A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma","status":"RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2021-05-24","conditions":["Plasmablastic Lymphoma","Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":15,"completionDate":"2030-07"},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":["Rhegmatogenous Retinal Detachment"],"enrollment":168,"completionDate":"2027-01-30"},{"nctId":"NCT03742258","phase":"PHASE1","title":"Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-03-13","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"],"enrollment":12,"completionDate":"2024-02-08"},{"nctId":"NCT02420717","phase":"PHASE2","title":"Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-15","conditions":["Recurrent B Acute Lymphoblastic Leukemia","Recurrent Ph-Like Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia","Refractory Ph-Like Acute Lymphoblastic Leukemia"],"enrollment":11,"completionDate":"2021-01-20"},{"nctId":"NCT05008224","phase":"PHASE2","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-10-07","conditions":["Classical Hodgkin Lymphoma"],"enrollment":146,"completionDate":"2024-05-26"},{"nctId":"NCT04752163","phase":"PHASE1,PHASE2","title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-03-25","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelomonocytic Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":17,"completionDate":"2023-11-08"},{"nctId":"NCT05947422","phase":"","title":"CT Quantitative Assessment of Interstitial Lung Disease","status":"RECRUITING","sponsor":"Assiut University","startDate":"2023-12-01","conditions":["Interstitial Lung Disease"],"enrollment":70,"completionDate":"2025-12-30"},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1895,"completionDate":"2025-03-31"},{"nctId":"NCT06249191","phase":"PHASE1,PHASE2","title":"Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-06-13","conditions":["Diffuse Large B-Cell Lymphoma","High Grade B-Cell Lymphoma"],"enrollment":30,"completionDate":"2027-04-01"},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":["Lymphoblastic Lymphoma, Childhood"],"enrollment":683,"completionDate":"2027-11-22"},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2024-12-31"},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":["Prostatic Neoplasms"],"enrollment":806,"completionDate":"2024-02-08"},{"nctId":"NCT05466396","phase":"","title":"Lung Health of Early COPD: A Multi-center Cohort Study","status":"RECRUITING","sponsor":"Ting YANG","startDate":"2022-08-01","conditions":["COPD"],"enrollment":1550,"completionDate":"2027-12-31"},{"nctId":"NCT00390793","phase":"PHASE2","title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-28","conditions":["Acute Lymphoblastic Leukemia","BCR-ABL1 Fusion Protein Expression","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","t(9;22)"],"enrollment":107,"completionDate":"2024-02-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006604","UNII":"IF8PQP966U","CHEBI":"CHEBI:135572","INN_ID":"1457","RXNORM":"12473","UMLSCUI":"C0044955","ChEMBL_ID":"CHEMBL2105359","KEGG_DRUG":"D07230","DRUGBANK_ID":"DB13208","PUBCHEM_CID":"20055008","MESH_SUPPLEMENTAL_RECORD_UI":"C036266"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H02AB11","allCodes":["H02AB11"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dacorsol, also known as prednylidene, is a small molecule drug in the prednylidene class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential uses of Dacorsol. Due to its lack of FDA approval, it is not currently available as a prescription medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}